Drug intelligence / Profile preview

dithranol + tazarotene

Development stage: Unknown
Lead developer: Allergan
Modality: Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
Administration: Topical

Overview

Dithranol + tazarotene is a combination topical treatment for psoriasis. This combination therapy has been shown to significantly increase the antipsoriatic effectiveness compared to dithranol monotherapy. Tazarotene, a retinoid that works by binding to retinoic acid receptors, enhances the efficacy of dithranol, which is a traditional antipsoriatic agent. Clinical studies have demonstrated that this combination leads to faster healing and greater reduction in Psoriasis Area and Severity Index (PASI) scores, though it may cause increased skin irritation.

Targets

RARG (Retinoic acid receptor gamma)RARB (Retinoic acid receptor beta)

Beyond the preview

Go deeper on dithranol + tazarotene.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dithranol + tazarotene.

Explore the full profile